Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Cancer drugs linked to severe chronic peripheral nerve pain for 4 in every 10 patients

Written by | 3 Feb 2025

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis… read more.

Pfizer to present new genitourinary cancer research at ASCO GU 2025

Written by | 1 Feb 2025

Pfizer Inc. will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February… read more.

Datroway approved in the U.S. for patients with previously treated metastatic HR Positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 31 Jan 2025

Datroway  (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC… read more.

Muscular strength and good physical fitness linked to lower risk of death in people with cancer

Written by | 25 Jan 2025

Muscular strength and good physical fitness are linked to a significantly lower risk of death from any cause in people with cancer, finds a pooled data analysis of… read more.

Trastuzumab emtansine improves outcomes in HER2-positive breast cancer

Written by | 17 Jan 2025

Researchers report that adjuvant (post-surgical) trastuzumab emtansine (T-DM1) treatment of women with high-risk HER2-positive breast cancer has reduced their long-term risk of death or invasive disease by 46%… read more.

NICE (UK) positive for Kimmtrak (tebentafusp) for treating advanced uveal melanoma – Immunocore Ltd

Written by | 16 Jan 2025

NICE (UK): 1.1 Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides… read more.

Bayer submits application in China for third indication of darolutamide

Written by | 13 Jan 2025

Bayer has filed an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for marketing authorization of the oral androgen receptor inhibitor… read more.

Supplemental approval of Opdivo + cisplatin + gemcitabine for treatment of unresectable urothelial carcinoma in Japan – Ono Pharma

Written by | 4 Jan 2025

Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.  announced that Ono has received a supplemental approval of Opdivo (generic name: nivolumab) Intravenous Infusion (“Opdivo”), an anti-PD-1 antibody, in… read more.

FDA approves Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma – Checkpoint Therapeutics

Written by | 3 Jan 2025

Checkpoint Therapeutics, Inc. announced that the FDA has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who… read more.

New and updated data for Roche’s fixed-duration Lunsumio at ASH 2024 reinforce its potential to improve outcomes for people with lymphoma – Roche

Written by | 2 Jan 2025

Roche announced  that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented at the 66th American Society of Hematology (ASH) Annual Meeting &… read more.

Results from phase III NATALEE trial of Kisqal (ribociclib) + endocrine therapy show sustained reduction of recurrence in HER+/HER2- early breast cancer – Novartis

Written by | 31 Dec 2024

Novartis announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqal (ribociclib) that underscore the extended efficacy beyond the duration of treatment in… read more.

Coffee and tea consumption tied to lower risk of head and neck cancers

Written by | 26 Dec 2024

A meta-analysis of data from 14 studies suggests that consumption of coffee and tea is linked to a reduced risk of head and neck cancer, including cancers of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.